A Randomized Control Trial of ZEPHYRx Gamified Incentive Spirometry Compared to Traditional Spirometry
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT04429009|
Recruitment Status : Not yet recruiting
First Posted : June 11, 2020
Last Update Posted : June 23, 2021
|Condition or disease||Intervention/treatment||Phase|
|Thoracic Surgery Respiratory Therapy||Device: ZEPHYRx Respiratory Therapy (RT) System Device: Standard Incentive Spirometer||Not Applicable|
Lobectomy and wedge resection patients at University of Rochester Medical Center meeting the eligibility criteria will be screened and consented by members of the research team prior to surgery at their pre-operative clinic visit. Once a subject meets the inclusion criteria for this study, the subject will be randomly assigned to one of the two arms of this study by a flip of a coin. To ensure that we meet the predicted 50 subjects in each arm of the study, every second subject enrolled will be assigned to the opposite arm of the previously assigned subject.
Subjects enrolled in the study arm:
Following surgery or extubation, and once no longer under the influence of anesthesia, the patient enrolled into the study arm will be provided with a ZEPHYRx incentive spirometer device connected to an Amazon Kindle Fire HD Tablet. A respiratory therapist, nurse, doctor, or research team member will teach the subject how to use the device and the tablet, and walk them through the first series of breaths. A built-in bell reminder in the device will ring once every hour between the hours of 8:00 a.m. and 8:00 p.m. to remind patients to use the device, this feature is part of the research and a feature programmed into the device. Additionally, subjects will answer questions on their tablet about pain level on a scale of 0-10 before and after each round of game play. At discharge, the subjects in the study arm will return their assigned tablet and will be issued a standard incentive spirometer to continue respiratory therapy at home, per standard of care. Subjects in the study arm will not be held responsible for lost, stolen or damaged tablets or incentive spirometers. The subject in the study arm may choose to keep or discard the ZEPHYRx incentive spirometer device. The device will record subject usage, including number of breaths, number of sessions, total time the device was in use, inspiratory volumes, and pain level (0-10) before and after each round of game play.
Subjects enrolled in the control arm:
Following surgery or extubation, and once no longer under the influence of anesthesia, the patient enrolled in the control arm will meet with an RT, nurse, doctor, or research team member to receive an FDA approved incentive spirometry device and appropriate training thus initiating the study. Routine respiratory care involves the use of a standard incentive spirometer that is not a digital device and does not include any built-in reminder. As per routine care, the nurse or respiratory therapist will remind the subjects in both arms of the study to perform their respiratory therapy of at least 10 breaths per hour. In order to obtain data comparable to what the ZEPHYRx respiratory therapy system will collect, similar data will be collected from subjects in the control arm on a data sheet by an RT, nurse, doctor, or research team member 3 times a day until the subject is discharged. The only questionnaire will be the standard of care pain scale questions which the subjects in the control arm will have to complete in written form. Upon discharge, subjects in the control arm of the study will be allowed to keep their standard of care incentive spirometer in order to continue respiratory therapy at home, per standard of care. Subjects in the control arm will not be held responsible for lost, stolen or damaged incentive spirometers.
On a daily basis, a member of the research team will check that the device(s) is/are working correctly and will answer any questions the subject may have regarding the study or device.
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||100 participants|
|Intervention Model:||Parallel Assignment|
|Intervention Model Description:||All lobectomy and wedge resection patients meeting the inclusion criteria will be recruited (from the start of the study date until recruitment goal it reached) and consenting participants will be randomized to a study arm or a control arm. Each arm will consist of 50 subjects.|
|Masking:||None (Open Label)|
|Official Title:||A Randomized Control Trial of ZEPHYRx Gamified Incentive Spirometry Compared to Traditional Spirometry|
|Estimated Study Start Date :||September 1, 2021|
|Estimated Primary Completion Date :||January 31, 2022|
|Estimated Study Completion Date :||February 28, 2022|
Experimental: Active Study Group
Participants in this group will be prescribed to use the ZEPHYRx RT device for incentive spectrometer once every hour during waking hours to perform a series of 10 deep breaths. The novel ZEPHYRx RT system consists three components:
Device: ZEPHYRx Respiratory Therapy (RT) System
A breath controlled video game system for respiratory therapy
Active Comparator: Control Group
Participants in this group will be prescribed to routine respiratory care, Routine respiratory care involves the use of a standard incentive spirometer that is not a digital device and does not include any built-in reminder. As per routine care, the nurse or respiratory therapist will remind the subjects to perform a series of at least 10 deep breaths every hour.
Device: Standard Incentive Spirometer
A simple (not digital) plastic device that contains a piston that rises inside the device and measures the volume of your breath
- Adherence to prescribed spirometry routine [ Time Frame: From extubation post-surgery to hospital discharge (estimated average of 2-4 days) ]Number of deep breaths taken per day with the prescribed device
- Lung Volume [ Time Frame: From extubation post-surgery to hospital discharge (estimated average of 2-4 days) ]Average daily inspiratory volume of the breaths taken with the prescribed device. Recorded 3 times per day by nurse or RT for the control group, and recorded at each use by the device for the active study group
- Hospital Readmission [ Time Frame: 30 days post discharge ]Hospital Readmission within 30 days of discharge
- Atelectasis [ Time Frame: Evaluated for any required x-ray procedures during length of post-operated hospital stay (estimated 2-4 days per patient) ]Degree of Atelectasis assessed from chest radiography on a 5 point scale, where high scores correspond to more severe disease (1. no apparent disease, 2. subsegmental atelectasis, 3. segmental atelectasis, 4. lobar atelectasis, or 5. pneumonia)
- Device Usability [ Time Frame: At time of discharge (estimated to be 2-4 days post surgery extubation) ]A brief survey including likert scale questions on usability, and open ended feedback. Questions will be asked on a 5 point scale (1. strongly agree, 2. somewhat agree, 3. Neutral, 4. somewhat disagree, strongly disagree), with lower scores corresponding to better acceptance of the device.
- Pain Scale pre and post exercises [ Time Frame: Recorded before and after each session with the device for the treatment group, and by a nurse via paper survey 3 times per day for the control group during the length of hospital stay (estimated 2-4 days per patient) ]A measure of pain on the 0-10 Wong-Baker FACES pain scale that uses images of faces to determine pain level. 0 = no hurt (happy face), 10 = worst hurt (crying face)
- Length of Stay [ Time Frame: From extubation post-surgery to hospital discharge (estimated average of 2-4 days) ]Post Operative Hospital Length of Stay
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04429009
|Contact: Wendy Linville, BA||(585) 276-3194||Wendy_Linville@urmc.rochester.edu|
|Contact: Kevin Kapcio, MD||(585) 273-5229||Kevin_Kapcio@urmc.rochester.edu|
|Principal Investigator:||Michal Lada, MD||University of Rochester|